138 related articles for article (PubMed ID: 1691921)
21. [Prognostic factors affecting survival and response in patients with advanced non-small cell lung cancer treated with combination chemotherapy].
Takifuji N; Fukuoka M; Negoro S; Takada M; Kusunoki Y; Matsui K; Masuda N; Ryu S; Sakai N; Kubota K
Gan To Kagaku Ryoho; 1990 Mar; 17(3 Pt 2):429-34. PubMed ID: 2157364
[TBL] [Abstract][Full Text] [Related]
22. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.
Paz-Ares L; de Marinis F; Dediu M; Thomas M; Pujol JL; Bidoli P; Molinier O; Sahoo TP; Laack E; Reck M; Corral J; Melemed S; John W; Chouaki N; Zimmermann AH; Visseren-Grul C; Gridelli C
Lancet Oncol; 2012 Mar; 13(3):247-55. PubMed ID: 22341744
[TBL] [Abstract][Full Text] [Related]
23. A randomized study of cisplatin versus cisplatin plus vindesine for non-small cell lung carcinoma.
Kawahara M; Furuse K; Kodama N; Yamamoto M; Kubota K; Takada M; Negoro S; Kusunoki Y; Matui K; Takifuji N
Cancer; 1991 Aug; 68(4):714-9. PubMed ID: 1649683
[TBL] [Abstract][Full Text] [Related]
24. Moderate dose-intensive chemotherapy for patients with non-small cell lung cancer: randomized trial, can it improve survival of patients with good performance status?
Masutani M; Tsujino I; Fujie T; Yamaguchi M; Miyagi K; Yano T; Takahashi N; Koya Y; Horie T
Oncol Rep; 1999; 6(5):1045-50. PubMed ID: 10425301
[TBL] [Abstract][Full Text] [Related]
25. Phase II study of concurrent radiotherapy and chemotherapy for unresectable stage III non-small-cell lung cancer. Southern Osaka Lung Cancer Study Group.
Furuse K; Kubota K; Kawahara M; Kodama N; Ogawara M; Akira M; Nakajima S; Takada M; Kusunoki Y; Negoro S
J Clin Oncol; 1995 Apr; 13(4):869-75. PubMed ID: 7707113
[TBL] [Abstract][Full Text] [Related]
26. Drug delivery analysis of the Canadian multicenter trial in non-small-cell lung cancer.
Murray N; Coppin C; Coldman A; Pater J; Rapp E
J Clin Oncol; 1994 Nov; 12(11):2333-9. PubMed ID: 7964949
[TBL] [Abstract][Full Text] [Related]
27. Benefits and adverse events among elderly patients receiving concurrent chemoradiotherapy for locally advanced non-small cell lung cancer: analysis of the Okayama Lung Cancer Study Group trial 0007.
Takigawa N; Kiura K; Segawa Y; Hotta K; Tamaoki A; Tokuda Y; Nagata T; Watanabe K; Gemba K; Moritaka T; Horita N; Takeda H; Okimoto N; Takemoto M; Matsuo K; Shinkai T; Tabata M; Ueoka H; Kanazawa S; Tanimoto M
J Thorac Oncol; 2011 Jun; 6(6):1087-91. PubMed ID: 21415777
[TBL] [Abstract][Full Text] [Related]
28. Random prospective study of vindesine versus vindesine plus high-dose cisplatin versus vindesine plus cisplatin plus mitomycin C in advanced non-small-cell lung cancer.
Einhorn LH; Loehrer PJ; Williams SD; Meyers S; Gabrys T; Nattan SR; Woodburn R; Drasga R; Songer J; Fisher W
J Clin Oncol; 1986 Jul; 4(7):1037-43. PubMed ID: 3088219
[TBL] [Abstract][Full Text] [Related]
29. Cisplatin and vindesine combination chemotherapy for non-small cell lung cancer: a randomized trial comparing two dosages of cisplatin.
Shinkai T; Saijo N; Eguchi K; Sasaki Y; Tominaga K; Sakurai M; Suga J; Miyaoka H; Sano T; Keicho N
Jpn J Cancer Res; 1986 Aug; 77(8):782-9. PubMed ID: 3019976
[TBL] [Abstract][Full Text] [Related]
30. Induction chemotherapy in non small cell lung cancer stage IIIa-b and IV and second-line treatment.
Stathopoulos GP; Dafni UG; Malamos NA; Rigatos S; Kouvatseas G; Moschopoulos N
Anticancer Res; 1999; 19(4C):3543-8. PubMed ID: 10629650
[TBL] [Abstract][Full Text] [Related]
31. Neoadjuvant vindesine, etoposide, and cisplatin for locally advanced non-small cell lung cancer. Final report of a phase 2 study.
Vokes EE; Bitran JD; Hoffman PC; Ferguson MK; Weichselbaum RR; Golomb HM
Chest; 1989 Jul; 96(1):110-3. PubMed ID: 2544349
[TBL] [Abstract][Full Text] [Related]
32. Chemotherapy of advanced non-small-cell lung cancer: a randomized trial of three cis-platin-based chemotherapy regimens.
Hainsworth JD; Johnson DH; Hande KR; Greco FA
Am J Clin Oncol; 1989 Aug; 12(4):345-9. PubMed ID: 2547305
[TBL] [Abstract][Full Text] [Related]
33. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer.
Scagliotti GV; Fossati R; Torri V; Crinò L; Giaccone G; Silvano G; Martelli M; Clerici M; Cognetti F; Tonato M;
J Natl Cancer Inst; 2003 Oct; 95(19):1453-61. PubMed ID: 14519751
[TBL] [Abstract][Full Text] [Related]
34. Cisplatin, vindesine, mitomycin-C and 13-cis retinoic acid in the treatment of advanced non small cell lung cancer. A phase II pilot study.
Recchia F; Sica G; De Filippis S; Rosselli M; Saggio G; Guerriero G; Pompili P; Rea S
Anticancer Res; 2000; 20(3B):1985-90. PubMed ID: 10928138
[TBL] [Abstract][Full Text] [Related]
35. Combination chemotherapy with mitomycin, vindesine, and cisplatin for non-small cell lung cancer. Association of antitumor activity with initial tumor burden and treatment center.
Joss RA; Bürki K; Dalquen P; Schatzmann E; Leyvraz S; Cavalli F; Ludwig C; Siegenthaler P; Alberto P; Stahel R
Cancer; 1990 Jun; 65(11):2426-34. PubMed ID: 2159837
[TBL] [Abstract][Full Text] [Related]
36. Cisplatin, epirubicin, and vindesine with or without lonidamine in the treatment of inoperable nonsmall cell lung carcinoma: a multicenter randomized clinical trial.
Ianniello GP; De Cataldis G; Comella P; Scarpati MD; Maiorino A; Brancaccio L; Cioffi R; Lombardi A; Carnicelli P; Tinessa V
Cancer; 1996 Jul; 78(1):63-9. PubMed ID: 8646728
[TBL] [Abstract][Full Text] [Related]
37. A phase II study of cisplatin, vindesine and continuously infused 5-fluorouracil in the treatment of advanced non-small-cell lung cancer. Osaka Lung Cancer Chemotherapy Study Group.
Nakano T; Ikegami H; Nakamura S; Kawase T; Nishikawa H; Yokota S; Yoshida M; Tachibana T; Igarashi T; Komuta K; Higashino K
Br J Cancer; 1996 May; 73(9):1096-100. PubMed ID: 8624270
[TBL] [Abstract][Full Text] [Related]
38. [Chemotherapy of advanced non-small cell bronchial cancer with mitomycin C/ifosfamide versus mitomycin C/vindesine versus cisplatin/etoposide--a prospective randomized study].
Gatzemeier U; Heckmayr M; Hossfeld DK; Kaukel E; Koschel G; Neuhauss R
Pneumologie; 1990 Feb; 44 Suppl 1():258-60. PubMed ID: 2164194
[TBL] [Abstract][Full Text] [Related]
39. [A pilot study of induction chemotherapy with cisplatin, mitomycin C and vindesine for stage III N2 non-small cell lung cancer].
Nishiwaki Y; Nagai K; Kodama T; Nishiyama H; Hojo H; Matsumoto T
Nihon Kyobu Shikkan Gakkai Zasshi; 1993 Dec; 31 Suppl():203-11. PubMed ID: 8007467
[TBL] [Abstract][Full Text] [Related]
40. [Cisplatin, doxorubicin and vindesine in the treatment of advanced non-small cell lung cancer].
Akiyama J; Sato A; Honda K; Chida K; Watanabe T; Okano H; Okano A; Taniguchi M; Genma H; Aoki H
Gan To Kagaku Ryoho; 1991 Mar; 18(3):419-24. PubMed ID: 1848420
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
